VRNA

Verona Pharma plc (VRNA) | Rumor.io

Verona Pharma

VRNA

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)91%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about VRNA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% -0.01

Aug 20

Verona Pharma plc ($VRNA) is strategically positioned in the biofarmaceutical market with promising advancements in respiratory treatments.
The company has had a decent start to the year, with a notable achievement in 2024.
There is a mention of a potential home run for $VRNA in 2024, but the exact context is unclear.

Generated by AI

Sentiment

Of the messages about VRNA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +18	83.62% -9
Bearish	—	0%	0% -18	16.38% +9

Bullish· Jul 10

Verona Pharma's stock has experienced a 1,997% increase over five years, with some investors making over 5x their initial investment.
Merck's acquisition of Verona Pharma is seen as a potential catalyst for further growth, with some analysts predicting significant upside potential and a possible increase in Merck's bid.
The company's robust technical indicators, including trading above its 50-day and 200-day moving averages, suggest positive momentum, although some analysts have noted potential volatility and the need for a more experienced CEO.

Bearish· Jul 9

$VRNA was sold for 12x 2027 revenue estimates, making its current price seem too low.
The stock's current price is a 9-23% premium over its recent lows, which some consider an "eyewash" or "low ball offer".
The company's slow launch and expiring patents have led some to question its long-term viability, with one investor comparing it to a "biotech graveyard".

Generated by AI

Topics

Of the messages about VRNA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	2.09%
Macro	—	—	—	0.11%
Earnings	—	—	—	0.94%
Controversies	—	—	—	1.02%
Announcements	—	—	—	93.83%
Analysts	—	—	—	2.01%

Earnings· Nov 5

Verona Pharma reports Q3 GAAP EPS of -£0.096.
Verona Pharma's cash and cash equivalents stood at £33.82M as of Q3.
Verona Pharma has released its Q3 results.

Announcements· Jul 10

Merck will acquire Verona Pharma for $107 per American depositary share, a deal worth approximately $10 billion, to add Ohtuvayre, the first novel inhaled COPD treatment in over 20 years.
The deal's closing is subject to shareholder approval, sanction by the High Court of Justice of England and Wales, and regulatory clearances, with a primary window for a competing bid likely emerging within 14-56 days from the announcement on July 9, 2025.
A competing bidder would need to secure financing and internal approval, which could add 1-3 weeks, and may face a $100 million termination fee if Verona accepts a superior proposal, potentially deterring bidders unless they offer a significantly higher price.

Technical Analysis· Dec 21

$VRNA has a potential breakout to $25 if it can break through resistance at $23.40, but there are smaller sell orders lined up before that.
The RSI is turning, which could increase momentum and help $VRNA reach its target price.
$VRNA has been in an uptrend since December 20, 2022, due to the momentum indicator exceeding the 0 level.

Generated by AI

Community

Of the messages about VRNA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	88.48%	58.68%
Newcomers	—	0%	11.52%	41.32%

Regulars· Aug 20

The regulars are focused on Verona Pharma's performance, specifically mentioning a quiet 1H in 2024 and a strong 2H in 2025.
The VRNA regulars are anticipating a decent year for the company, with a notable achievement in hitting a "home run" earlier this year.
There is a mention of a 2025 target for the company, referred to as the "Velan beast".

Newcomers· Jul 10

$VRNA is being acquired by Merck for $10B, with the acquisition expected to be completed in 10-12 months, adding Ohtuvayre, the first new inhaled COPD maintenance therapy in 20+ years, to Merck's portfolio.
Keytruda, a key product for Merck, is set to go off-patent in 2028, and the company faces a significant revenue decline, making the acquisition a strategic move to bolster its product lineup.
Analyst Tiago Fauth has downgraded his price target for $VRNA to $107, citing a decrease in potential upside, with a rating of Equal-Weight.

Generated by AI

News

Vor Bio Appoints David Zaccardelli to Board of Directors

Detailed price information for Vor Biopharma Inc (VOR-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Also Discussed

Investors talking about VRNA also mention

#	Name	Attention
1	SWTX - SpringWorks Therapeutics, Inc.	——
2	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
3	UroGen Pharma Ltd.URGN	0%new
4	Janux Therapeutics, Inc.JANX	0%0
5	DAWN - Day One Biopharmaceuticals, Inc.	——
6	Abivax SAABVX	0.01%-0.01
7	Edgewise Therapeutics Inc.EWTX	0%new
8	Travere Therapeutics Inc.TVTX	0%0
9	TERN - Terns Pharmaceuticals, Inc.	——
10	Syndax Pharmaceuticals, Inc.SNDX	0%+0

Verona Pharma plc

Location

Social

What share of all stock conversation is about VRNA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% -0.01

Aug 20

Verona Pharma plc ($VRNA) is strategically positioned in the biofarmaceutical market with promising advancements in respiratory treatments.
The company has had a decent start to the year, with a notable achievement in 2024.
There is a mention of a potential home run for $VRNA in 2024, but the exact context is unclear.

Generated by AI

Sentiment

Of the messages about VRNA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +18	83.62% -9
Bearish	—	0%	0% -18	16.38% +9

Bullish· Jul 10

Verona Pharma's stock has experienced a 1,997% increase over five years, with some investors making over 5x their initial investment.
Merck's acquisition of Verona Pharma is seen as a potential catalyst for further growth, with some analysts predicting significant upside potential and a possible increase in Merck's bid.
The company's robust technical indicators, including trading above its 50-day and 200-day moving averages, suggest positive momentum, although some analysts have noted potential volatility and the need for a more experienced CEO.

Bearish· Jul 9

$VRNA was sold for 12x 2027 revenue estimates, making its current price seem too low.
The stock's current price is a 9-23% premium over its recent lows, which some consider an "eyewash" or "low ball offer".
The company's slow launch and expiring patents have led some to question its long-term viability, with one investor comparing it to a "biotech graveyard".

Generated by AI

Topics

Of the messages about VRNA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	2.09%
Macro	—	—	—	0.11%
Earnings	—	—	—	0.94%
Controversies	—	—	—	1.02%
Announcements	—	—	—	93.83%
Analysts	—	—	—	2.01%

Earnings· Nov 5

Verona Pharma reports Q3 GAAP EPS of -£0.096.
Verona Pharma's cash and cash equivalents stood at £33.82M as of Q3.
Verona Pharma has released its Q3 results.

Announcements· Jul 10

Merck will acquire Verona Pharma for $107 per American depositary share, a deal worth approximately $10 billion, to add Ohtuvayre, the first novel inhaled COPD treatment in over 20 years.
The deal's closing is subject to shareholder approval, sanction by the High Court of Justice of England and Wales, and regulatory clearances, with a primary window for a competing bid likely emerging within 14-56 days from the announcement on July 9, 2025.
A competing bidder would need to secure financing and internal approval, which could add 1-3 weeks, and may face a $100 million termination fee if Verona accepts a superior proposal, potentially deterring bidders unless they offer a significantly higher price.

Technical Analysis· Dec 21

$VRNA has a potential breakout to $25 if it can break through resistance at $23.40, but there are smaller sell orders lined up before that.
The RSI is turning, which could increase momentum and help $VRNA reach its target price.
$VRNA has been in an uptrend since December 20, 2022, due to the momentum indicator exceeding the 0 level.

Generated by AI

Community

Of the messages about VRNA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	88.48%	58.68%
Newcomers	—	0%	11.52%	41.32%

Regulars· Aug 20

The regulars are focused on Verona Pharma's performance, specifically mentioning a quiet 1H in 2024 and a strong 2H in 2025.
The VRNA regulars are anticipating a decent year for the company, with a notable achievement in hitting a "home run" earlier this year.
There is a mention of a 2025 target for the company, referred to as the "Velan beast".

Newcomers· Jul 10

$VRNA is being acquired by Merck for $10B, with the acquisition expected to be completed in 10-12 months, adding Ohtuvayre, the first new inhaled COPD maintenance therapy in 20+ years, to Merck's portfolio.
Keytruda, a key product for Merck, is set to go off-patent in 2028, and the company faces a significant revenue decline, making the acquisition a strategic move to bolster its product lineup.
Analyst Tiago Fauth has downgraded his price target for $VRNA to $107, citing a decrease in potential upside, with a rating of Equal-Weight.

Generated by AI

Verona Pharma

Social

Aug 20

Bullish· Jul 10

Bearish· Jul 9

Earnings· Nov 5

Announcements· Jul 10

Technical Analysis· Dec 21

Regulars· Aug 20

Newcomers· Jul 10

Vor Bio Appoints David Zaccardelli to Board of Directors

Also Discussed

Verona Pharma plc

Company Information

Location

Vor Bio Appoints David Zaccardelli to Board of Directors

Also Discussed

Social

Aug 20

Bullish· Jul 10

Bearish· Jul 9

Earnings· Nov 5

Announcements· Jul 10

Technical Analysis· Dec 21

Regulars· Aug 20

Newcomers· Jul 10